首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir
【24h】

Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir

机译:细胞色素P4503A不介导美沙酮与利托那韦-洛匹那韦之间的相互作用

获取原文
获取原文并翻译 | 示例
       

摘要

Plasma concentrations of orally administered methadone are reduced by the human immunodeficiency virus protease inhibitor combination ritonavir and lopinavir, but the mechanism is unknown. Methadone metabolism, clearance, and drug interactions have been attributed to CYP3A4, but this remains controversial. This investigation assessed the effects of acute (2 days) and steady-state (2 weeks) ritonavir-lopinavir on intravenous and oral methadone metabolism and clearance, hepatic and intestinal CYP3A4/5 activity (using the probe substrate intravenous and oral alfentanil), and intestinal transporter activity (using oral fexofenadine) in healthy volunteers. Plasma and urine concentrations of methadone and metabolite enantiomers, and other analytes, were determined by mass spectrometry. Acute and chronic ritonavir-lopinavir reduced plasma methadone enantiomer concentrations in half, with an average 2.6- and 1.5-fold induction of systemic and apparent oral methadone clearances. Induction was attributable to stereoselectively increased hepatic methadone N-demethylation, hepatic extraction, and hepatic clearance, and there was a strong correlation between methadone N-demethylation and clearance. Methadone renal clearance was unchanged. Alfentanil's systemic clearance and hepatic extraction, apparent oral clearance, and intestinal extraction were reduced to 25%, 16%, and 35% of control, indicating strong inhibition of hepatic and intestinal CYP3A activities. Ritonavir-lopinavir (acute > chronic) increased fexofenadine exposure, suggesting intestinal P-glycoprotein inhibition. No correlation was found between methadone clearance and CYP3A activity. Acute and steady-state ritonavir-lopinavir stereoselectively induced methadone N-demethylation and clearance, despite significant inhibition of hepatic and intestinal CYP3A activity. Ritonavir-lopinavir inhibited intestinal transporters activity but had no effect on methadone bioavailability. These results do not support a significant role for CYP3A or ritonavir-lopinavir-inhibitable intestinal transporters in single-dose methadone disposition.
机译:人免疫缺陷病毒蛋白酶抑制剂利托那韦和洛匹那韦的组合可降低口服美沙酮的血浆浓度,但机理尚不清楚。美沙酮的代谢,清除率和药物相互作用已归因于CYP3A4,但这仍存在争议。这项研究评估了急性(2天)和稳态(2周)利托那韦-洛匹那韦对静脉和口服美沙酮代谢和清除,肝和肠CYP3A4 / 5活性(使用探针底物静脉和口服阿芬太尼)的影响,以及健康志愿者的肠道转运蛋白活性(使用口服非索非那定)。美沙酮和代谢物对映异构体以及其他分析物的血浆和尿液浓度通过质谱法测定。急性和慢性利托那韦-洛匹那韦可将血浆美沙酮对映体浓度降低一半,平均诱导全身和明显的口服美沙酮清除率分别为2.6和1.5倍。归因于立体选择性增加的肝美沙酮N-去甲基化,肝提取和肝清除率,并且美沙酮N-去甲基化与清除率之间有很强的相关性。美沙酮的肾清除率未改变。 Alfentanil的全身清除率和肝提取率,表观口腔清除率和肠提取率分别降低至对照组的25%,16%和35%,表明对肝和肠CYP3A活性的抑制作用强。利托那韦-洛匹那韦(急性>慢性)增加了非索非那定的暴露,表明肠道P-糖蛋白被抑制。在美沙酮清除率与CYP3A活性之间未发现相关性。急性和稳态的利托那韦-洛匹那韦立体选择性诱导美沙酮N-去甲基化和清除,尽管对肝和肠CYP3A活性有明显抑制作用。利托那韦-洛匹那韦抑制肠转运蛋白的活性,但对美沙酮的生物利用度没有影响。这些结果在单剂量美沙酮处置中不支持CYP3A或利托那韦-洛匹那韦抑制性肠道转运蛋白的重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号